PE64396A1 - Proteina accesoria del receptor de la interleucina 1 - Google Patents
Proteina accesoria del receptor de la interleucina 1Info
- Publication number
- PE64396A1 PE64396A1 PE1996000031A PE00003196A PE64396A1 PE 64396 A1 PE64396 A1 PE 64396A1 PE 1996000031 A PE1996000031 A PE 1996000031A PE 00003196 A PE00003196 A PE 00003196A PE 64396 A1 PE64396 A1 PE 64396A1
- Authority
- PE
- Peru
- Prior art keywords
- accessory protein
- receptor
- polynucleotide
- same
- mentioned
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
SE REFIERE A: i) EL POLINUCLEOTIDO QUE COMPRENDE UNA SECUENCIA DE ADN SELECCIONADA DE: a) UN POLINUCLEOTIDO QUE TIENE LA SECUENCIA SEQ ID NO:1; b) UN POLINUCLEOTIDO QUE HIBRIDA CON EL ADN DE (a) EN CONDICIONES RESTRICTIVAS; c) UN POLINUCLEOTIDO QUE DIFIERE EN LA SECUENCIA DE CODONES DEBIDO A LA DEGENERACION DEL CODIGO GENETICO; QUE CODIFICA LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1, O UN FRAGMENTO ACTIVO DE LA MISMA; ii) A LA CELULA HOSPEDADORA QUE CONTIENE UN VECTOR DE EXPRESION O AL VECTOR QUE CONTIENE AL POLINUCLEOTIDO MENCIONADO; iii) A LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1 O UN FRAGMENTO ACTIVO DE LA MISMA, TAL COMO LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1 HUMANA, QUE ES CODIFICADA POR EL POLINUCLEOTIDO MENCIONADO; iV) UN ANTICUERPO MONOCLONAL QUE SE UNE ESPECIFICAMENTE A LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1 HUMANA QUE IMPIDE LA ACTIVACION DEL COMPLEJO DEL RECEPTOR DE LA IL-1 MEDIENTE LA IL-1; V) EL PROCEDIMIENTO DE PREPARACION DE UNA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1 QUE COMPRENDE: a) EXPRESION DE UN POLIPEPTIDO CODIFICADO POR UN ADN MENCIONADO EN UN HOSPEDERO ADECUADO; b) AISLAMIENTO DE DICHA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1; c) CONVERSION DE LA MISMA EN UN ANALOGO EN EL CUAL HAN SIDO MODIFICADOS GRUPOS SECUNDARIOS; Vi) PREPARACION DE UN ANTICUERPO DE LA PROTEINA ACCESORIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37626895A | 1995-01-23 | 1995-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE64396A1 true PE64396A1 (es) | 1997-01-28 |
Family
ID=23484321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1996000031A PE64396A1 (es) | 1995-01-23 | 1996-01-15 | Proteina accesoria del receptor de la interleucina 1 |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0808365A1 (es) |
| JP (1) | JPH10512453A (es) |
| AR (1) | AR003919A1 (es) |
| AU (1) | AU4537096A (es) |
| BR (1) | BR9606837A (es) |
| CA (1) | CA2210724A1 (es) |
| CO (1) | CO4480033A1 (es) |
| CZ (1) | CZ208197A3 (es) |
| EA (1) | EA199700265A1 (es) |
| FI (1) | FI973089A (es) |
| HU (1) | HUP9702458A2 (es) |
| IL (1) | IL116796A0 (es) |
| MX (1) | MX9705501A (es) |
| NO (1) | NO973404D0 (es) |
| PE (1) | PE64396A1 (es) |
| PL (1) | PL321538A1 (es) |
| TR (1) | TR199700652T1 (es) |
| WO (1) | WO1996023067A1 (es) |
| ZA (1) | ZA96333B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7011696A (en) * | 1996-08-26 | 1998-03-19 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| US6974682B1 (en) | 1996-08-26 | 2005-12-13 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| CA2273852C (en) | 1996-12-06 | 2009-09-29 | Amgen Inc. | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| EP0979282A1 (en) | 1997-04-30 | 2000-02-16 | F. Hoffmann-La Roche Ag | Rat st38.2 chemokine |
| US6280955B1 (en) * | 1997-12-16 | 2001-08-28 | Tularik Inc. | Interleukin-1 receptor accessory proteins, nucleic acids and methods |
| JP2001526892A (ja) | 1997-12-23 | 2001-12-25 | イミュネックス・コーポレーション | Ｓｉｇｉｒｒｄｎａおよびポリペプチド |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| US7049095B2 (en) | 2000-10-31 | 2006-05-23 | Immunex Corporation | DNA encoding IL-1 receptor accessory protein |
| GB2375604A (en) * | 2001-05-18 | 2002-11-20 | Warner Lambert Co | Methods for screening using interleukin soluble trimolecular complex |
| YU103003A (sh) | 2001-06-26 | 2006-05-25 | Abgenix Inc. | Antitela za opgl |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| EP1450837A4 (en) * | 2001-08-07 | 2006-01-04 | Immunex Corp | INTERLEUKIN-1 RECEPTORS IN THE TREATMENT OF DISEASES |
| NZ538569A (en) | 2002-09-06 | 2009-02-28 | Amgen Inc | Therapeutic human anti-IL-1R1 monoclonal antibody |
| PT1729810T (pt) | 2004-04-02 | 2018-11-22 | Swedish Orphan Biovitrum Ab Publ | Métodos de redução da agregação de il-ira |
| PL1751175T3 (pl) * | 2004-05-05 | 2013-03-29 | Valorisation Recherche Soc En Commandite | Antagoniści receptora IL-1, kompozycje i sposoby leczenia |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| EP2366786A3 (en) * | 2005-05-05 | 2012-08-29 | VALORISATION HSJ, Société en Commandite | Cytokine receptor modulators and uses thereof |
| US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| PE20070684A1 (es) | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
| WO2009120903A2 (en) | 2008-03-26 | 2009-10-01 | Cellerant Therapeutics, Inc. | Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| GB2472856B (en) * | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| CA2824719C (en) | 2011-01-19 | 2020-06-02 | Cantargia Ab | Anti-il1rap antibodies and their use for treating solid tumours |
| JP6153874B2 (ja) | 2011-02-09 | 2017-06-28 | ナテラ， インコーポレイテッド | 非侵襲的出生前倍数性呼び出しのための方法 |
| AU2012273153A1 (en) * | 2011-06-21 | 2013-05-02 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| EP4428863A2 (en) | 2015-05-11 | 2024-09-11 | Natera, Inc. | Methods and compositions for determining ploidy |
| EP3313887A2 (en) | 2015-06-26 | 2018-05-02 | MAB Discovery GmbH | Monoclonal anti-il-1racp antibodies |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| US10041044B2 (en) | 2016-07-29 | 2018-08-07 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| US11773434B2 (en) | 2017-06-20 | 2023-10-03 | The Medical College Of Wisconsin, Inc. | Assessing transplant complication risk with total cell-free DNA |
| US12084720B2 (en) | 2017-12-14 | 2024-09-10 | Natera, Inc. | Assessing graft suitability for transplantation |
| CA3090426A1 (en) | 2018-04-14 | 2019-10-17 | Natera, Inc. | Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna |
| TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
| US11931674B2 (en) | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
| WO2021236962A1 (en) | 2020-05-20 | 2021-11-25 | The Medical College Of Wisconsin, Inc. | Compositions and methods for inhibiting cytokine-release syndrome |
| CN114835799A (zh) * | 2021-05-28 | 2022-08-02 | 百奥赛图江苏基因生物技术有限公司 | Il1rap基因人源化非人动物的构建方法及应用 |
| WO2024062074A1 (en) | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
-
1996
- 1996-01-15 PE PE1996000031A patent/PE64396A1/es not_active Application Discontinuation
- 1996-01-16 ZA ZA96333A patent/ZA96333B/xx unknown
- 1996-01-17 MX MX9705501A patent/MX9705501A/es unknown
- 1996-01-17 BR BR9606837A patent/BR9606837A/pt unknown
- 1996-01-17 EA EA199700265A patent/EA199700265A1/ru unknown
- 1996-01-17 PL PL96321538A patent/PL321538A1/xx unknown
- 1996-01-17 TR TR97/00652T patent/TR199700652T1/xx unknown
- 1996-01-17 EP EP96901291A patent/EP0808365A1/en not_active Withdrawn
- 1996-01-17 JP JP8522598A patent/JPH10512453A/ja active Pending
- 1996-01-17 AU AU45370/96A patent/AU4537096A/en not_active Abandoned
- 1996-01-17 CZ CZ972081A patent/CZ208197A3/cs unknown
- 1996-01-17 HU HU9702458A patent/HUP9702458A2/hu unknown
- 1996-01-17 IL IL11679696A patent/IL116796A0/xx unknown
- 1996-01-17 WO PCT/EP1996/000181 patent/WO1996023067A1/en not_active Application Discontinuation
- 1996-01-17 CA CA002210724A patent/CA2210724A1/en not_active Abandoned
- 1996-01-19 AR ARP960101095A patent/AR003919A1/es unknown
- 1996-01-22 CO CO96002329A patent/CO4480033A1/es unknown
-
1997
- 1997-07-22 FI FI973089A patent/FI973089A/fi unknown
- 1997-07-23 NO NO973404A patent/NO973404D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU4537096A (en) | 1996-08-14 |
| CO4480033A1 (es) | 1997-07-09 |
| HUP9702458A2 (hu) | 1998-04-28 |
| EA199700265A1 (ru) | 1998-04-30 |
| TR199700652T1 (xx) | 1998-02-21 |
| MX9705501A (es) | 1997-10-31 |
| NO973404L (no) | 1997-07-23 |
| WO1996023067A1 (en) | 1996-08-01 |
| CZ208197A3 (en) | 1997-11-12 |
| CA2210724A1 (en) | 1996-08-01 |
| EP0808365A1 (en) | 1997-11-26 |
| IL116796A0 (en) | 1996-05-14 |
| FI973089A0 (fi) | 1997-07-22 |
| PL321538A1 (en) | 1997-12-08 |
| NO973404D0 (no) | 1997-07-23 |
| AR003919A1 (es) | 1998-09-30 |
| BR9606837A (pt) | 1998-05-26 |
| FI973089A (fi) | 1997-07-22 |
| ZA96333B (en) | 1996-07-23 |
| JPH10512453A (ja) | 1998-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE64396A1 (es) | Proteina accesoria del receptor de la interleucina 1 | |
| AR248044A1 (es) | Una secuencia de adn que codifica anticuerpos monoclonales humanizados contra interleuquinas humanas, metodo de obtencion y de seleccion de dichos anticuerpos, vector recombinante y celula huesped. | |
| FI882456A (fi) | Human proapolipoprotein a-i expression. | |
| ATE136908T1 (de) | Peptide und antikörper, die die integrin- ligandbindung inhibieren | |
| CA2096159A1 (en) | Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates | |
| IL86278A (en) | Endowing cells with antibody specificity using chimeric t cell receptor | |
| DK1015587T3 (da) | DcR3 polypeptid, en TNFR-homolog | |
| RU2014154067A (ru) | Специфичная к ткани-мишени антигенсвязывающая молекула | |
| ES2054601T3 (es) | Proteina con actividad de tipo citoquina, adn recombinante codante para esta proteina, celulas y microorganismos transformados. | |
| Porter | The structure of the heavy chain of immunoglobulin and its relevance to the nature of the antibody-combining site. The Second CIBA Medal Lecture. | |
| FI941048A (fi) | Geloniinipolypeptidin koodaavia DNA-sekvenssejä | |
| BR9500271B1 (pt) | seqüência de dna recombinante, vetor, células procarióticas e de fungo transformadas e proteìna com atividade sacarose-isomerase e com atividade de platinase e/ou trehalulase. | |
| EA201001190A1 (ru) | Выделенное антитело, специфически связанное с полипептидом, состоящее из последовательности аминокислотных остатков | |
| James et al. | Use of reversed-phase and ion-exchange batch extraction in the purification of bovine pituitary peptides | |
| DK1417222T3 (da) | Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop | |
| EP0815240A4 (en) | NOVEL KINASE-LIKE CYCLINE-LIKE PROTEINS AND METHODS OF APPLICATION THEREOF | |
| NO975565L (no) | Benstimulerende faktor | |
| Sherman et al. | Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia | |
| DK0667781T3 (da) | Peptidbaserede diagnostiske og terapeutiske midler til spondylarthropatier | |
| ATE75754T1 (de) | Monoklonale antikoerper gegen atriale, natriurethische peptide. | |
| DE60031414D1 (de) | Einkettige polypeptide enthaltend n-terminale troponin i fragmente und troponin c | |
| EP0643076A4 (en) | NOVEL PEPTIDE HAVING RECEPTOR ACTIVITY AND DNA ENCODING THE PEPTIDE. | |
| AR025482A1 (es) | Secuencia de adn que codifica una proteina capaz de ligarse a traf; vector que comprende dicha secuencia; celulas huespedes transformadas con dicho vector;proteinas iren codificadas por dicha secuencia; metodo para producir dicha proteina; anticuerpos especificos para dichas proteinas; metodo para m | |
| DE69132874D1 (de) | Für ein protein mit endochitinase-aktivität kodierendes rekombinantes gen | |
| FR2829774B1 (fr) | N-desoxyribosyltransferases de lactobacilles, sequences nucleotidiques correspondantes et leurs applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |